Similar stock images

Washington, United States Of America. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP | usage worldwide Credit: dpa/Alamy Live News - Stock PhotoWashington, United States Of America. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP | usage worldwide Credit: dpa/Alamy Live News
Albert Bourla, DVM, Ph.D., Chief Executive Officer of Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP /MediaPunch - Stock PhotoAlbert Bourla, DVM, Ph.D., Chief Executive Officer of Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP /MediaPunch
Albert Bourla, DVM, Ph.D., Chief Executive Officer ofPfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, USA, February 26, 2019. - A Covid-19 vaccine being developed by Pfizer and Germany’s BioNTech has been found to be more than 90 per cent effective, in a breakthrough that could make the shot available for use by the end of the year if drug authorities give it the green light. Photo by Chris Kleponis/CNP/ABACAPRESS.COM - Stock PhotoAlbert Bourla, DVM, Ph.D., Chief Executive Officer ofPfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, USA, February 26, 2019. - A Covid-19 vaccine being developed by Pfizer and Germany’s BioNTech has been found to be more than 90 per cent effective, in a breakthrough that could make the shot available for use by the end of the year if drug authorities give it the green light. Photo by Chris Kleponis/CNP/ABACAPRESS.COM
Washington, District of Columbia, USA. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of.Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP Credit: Chris Kleponis/CNP/ZUMA Wire/Alamy Live News - Stock PhotoWashington, District of Columbia, USA. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of.Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP Credit: Chris Kleponis/CNP/ZUMA Wire/Alamy Live News
Washington, United States Of America. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP | usage worldwide Credit: dpa/Alamy Live News - Stock PhotoWashington, United States Of America. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP | usage worldwide Credit: dpa/Alamy Live News
Albert Bourla, DVM, Ph.D., Chief Executive Officer ofPfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, USA, February 26, 2019. - A Covid-19 vaccine being developed by Pfizer and Germany’s BioNTech has been found to be more than 90 per cent effective, in a breakthrough that could make the shot available for use by the end of the year if drug authorities give it the green light. Photo by Chris Kleponis/CNP/ABACAPRESS.COM - Stock PhotoAlbert Bourla, DVM, Ph.D., Chief Executive Officer ofPfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, USA, February 26, 2019. - A Covid-19 vaccine being developed by Pfizer and Germany’s BioNTech has been found to be more than 90 per cent effective, in a breakthrough that could make the shot available for use by the end of the year if drug authorities give it the green light. Photo by Chris Kleponis/CNP/ABACAPRESS.COM
Washington, District of Columbia, USA. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of.Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP Credit: Chris Kleponis/CNP/ZUMA Wire/Alamy Live News - Stock PhotoWashington, District of Columbia, USA. 26th Feb, 2019. Albert Bourla, DVM, Ph.D., Chief Executive Officer of.Pfizer appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Credit: Chris Kleponis/CNP Credit: Chris Kleponis/CNP/ZUMA Wire/Alamy Live News
Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson (C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier Brandicourt, M.D., Chief Executive Officer Sanofi (R) appear - Stock PhotoRichard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson (C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier Brandicourt, M.D., Chief Executive Officer Sanofi (R) appear
Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson (C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier Brandicourt, M.D., Chief Executive Officer Sanofi (R) appear - Stock PhotoRichard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson (C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier Brandicourt, M.D., Chief Executive Officer Sanofi (R) appear
February 26, 2019 - Washington, District of Columbia, U.S. - Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson.(C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier - Stock PhotoFebruary 26, 2019 - Washington, District of Columbia, U.S. - Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson.(C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier
February 26, 2019 - Washington, District of Columbia, U.S. - Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson.(C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier - Stock PhotoFebruary 26, 2019 - Washington, District of Columbia, U.S. - Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. (L), Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca(2nd L), Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. (3rd L) Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals Johnson & Johnson.(C), Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. (3rd R), Albert Bourla, DVM, Ph.D. Chief Executive Officer, Pfizer(2nd R) and Olivier